Leucine aminopeptidase LyLAP enables lysosomal degradation of membrane proteins
Science · 28.03.2025 · 387 (6741)
DOI: 10.1126/science.adq8331 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, erschienen am 28.03.2025. Verfasst von Aakriti Jain und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, CA, USA. Hauptthemen laut MEDLINE: Lysosomes, Leucyl Aminopeptidase, Membrane Proteins, Pancreatic Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 102 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NIAID NIH HHS.
Abstract (Originalsprache)
Breakdown of every transmembrane protein trafficked to lysosomes requires proteolysis of their hydrophobic helical transmembrane domains. Combining lysosomal proteomics with functional genomic datasets, we identified lysosomal leucine aminopeptidase (LyLAP; formerly phospholipase B domain–containing 1) as the hydrolase most tightly associated with elevated endocytosis. Untargeted metabolomics and biochemical reconstitution demonstrated that LyLAP is a processive monoaminopeptidase with preference for amino-terminal leucine. This activity was necessary and sufficient for the breakdown of hydrophobic transmembrane domains. LyLAP was up-regulated in pancreatic ductal adenocarcinoma (PDA), which relies on macropinocytosis for nutrient uptake. In PDA cells, LyLAP ablation led to the buildup of undigested hydrophobic peptides, lysosomal membrane damage, and growth inhibition. Thus, LyLAP enables lysosomal degradation of membrane proteins and protects lysosomal integrity in highly endocytic cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Molecular and Cell Biology, University of California at Berkeley, Berkeley, CA, USA.
- Metabolic Research Group, de Duve Institute and WELBIO, Universite Catholique de Louvain, Brussels, Belgium.
- Department of Anatomy and Helen Diller Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
- Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, CA, USA.
- Department of Nutritional Sciences and Toxicology, University of California, Berkeley, Berkeley, CA, USA.
- Department of Pathology and Laboratory Medicine and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA.
ORCID-Profile: Aakriti Jain, Isaac Heremans, Gilles Rademaker, Tyler C Detomasi, Peter Rohweder, Grace A Hernandez, Suprit Gupta, Teresa von Linde, Martina Spacci, Jiayi Luo, James A Olzmann, David W Dawson, Charles S Craik, Guido Bommer, Roberto Zoncu
Förderung
- NIGMS NIH HHS
- NCI NIH HHS
- NIAID NIH HHS
Zitieren
APA
Jain, A., Heremans, I., Rademaker, G., Detomasi, T. C., Rohweder, P., Anderson, D., Zhang, J., Hernandez, G. A., Gupta, S., von Linde, T., Lange, M., Spacci, M., Luo, J., Citron, Y. R., Olzmann, J. A., Dawson, D. W., Craik, C. S., Bommer, G., Perera, R. M., & Zoncu, R. (2025). Leucine aminopeptidase LyLAP enables lysosomal degradation of membrane proteins. Science, 387(6741). https://doi.org/10.1126/science.adq8331
Vancouver
Jain A, Heremans I, Rademaker G, Detomasi TC, Rohweder P, Anderson D, et al. Leucine aminopeptidase LyLAP enables lysosomal degradation of membrane proteins. Science. 2025;387(6741). doi:10.1126/science.adq8331
BibTeX
@article{Jain2025,
author = {Jain, Aakriti and Heremans, Isaac and Rademaker, Gilles and Detomasi, Tyler C and Rohweder, Peter and Anderson, Dashiell and Zhang, Justin and Hernandez, Grace A and Gupta, Suprit and von Linde, Teresa and Lange, Mike and Spacci, Martina and Luo, Jiayi and Citron, Y Rose and Olzmann, James A and Dawson, David W and Craik, Charles S and Bommer, Guido and Perera, Rushika M and Zoncu, Roberto},
title = {Leucine aminopeptidase LyLAP enables lysosomal degradation of membrane proteins},
journal = {Science},
year = {2025},
volume = {387},
number = {6741},
doi = {10.1126/science.adq8331}
}
EUVIMED